Novel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomics
MetadataShow full item record
AuthorJiménez Luna, Cristina; Martin Blázquez, Ariadna; Diéguez Castillo, Carmelo; Díaz, Caridad; Martín Ruiz, José Luis; Genilloud, Olga
MetabolomicsUntargeted LC-HRMSDiagnosisPancreatogenic diabetes mellitusType 2 Diabetes MellitusChronic pancreatitisBiomarkers
Jimenez-Luna, C., Martin-Blazquez, A., Dieguez-Castillo, C., Diaz, C., Martin-Ruiz, J. L., Genilloud, O., ... & Caba, O. (2020). Novel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomics. Metabolites, 10(11), 423. [doi:10.3390/metabo10110423]
SponsorshipJunta de Andalucía PIN-0474-2016 PC-0549-2017 PC-0498-2017; Instituto de Salud Carlos III DTS17/00081; Fundación MEDINA, a public-private partnership of Merck Sharp and Dohme de España S.A./Universidad de Granada/Junta de Andalucía PIN-0474-2016
Pancreatogenic diabetes mellitus (T3cDM) is a highly frequent complication of pancreatic disease, especially chronic pancreatitis, and it is often misdiagnosed as type 2 diabetes mellitus (T2DM). A correct diagnosis allows the appropriate treatment of these patients, improving their quality of life, and various technologies have been employed over recent years to search for specific biomarkers of each disease. The main aim of this metabolomic project was to find di erential metabolites between T3cDM and T2DM. Reverse-phase liquid chromatography coupled to high-resolution mass spectrometry was performed in serum samples from patients with T3cDM and T2DM. Multivariate Principal Component and Partial Least Squares-Discriminant analyses were employed to evaluate between-group variations. Univariate and multivariate analyses were used to identify potential candidates and the area under the receiver-operating characteristic (ROC) curve was calculated to evaluate their diagnostic value. A panel of five di erential metabolites obtained an area under the ROC curve of 0.946. In this study, we demonstrate the usefulness of untargeted metabolomics for the di erential diagnosis between T3cDM and T2DM and propose a panel of five metabolites that appear altered in the comparison between patients with these diseases.